Shots:

• The exploratory P-l/ll study involves the assessment of ONCOS-102 + SoC CT (pemetrexed/cisplatin) as a 1L and 2L treatment in 31 patients with MPM
• Result: @18mos. follow up showed that mOS (18.2mos. vs 14.2mos.) and showed broad and powerful immune activation- associated with better survival outcome. The next survival analysis is planned in H1’21
• Targovax and Merck are currently reviewing the next steps for combining ONCOS-102 and Keytruda in MPM

 ­ Ref: PRNewswire | Image: Targovax